Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)

McGill University

$100,000.00

Deubiquitinase MYSM1 as an essential epigenetic regulator of hematopoiesis

FY 2022-23

Summary
Our blood is sustained by the daily production of hundreds of billions of new cells in our bone marrow in the process known as hematopoiesis. This process requires precise regulation of gene expression within the hematopoietic stem and progenitor cells (HSPCs), and its dysregulation can result in devastating hematologic disorders, such as inherited bone marrow failures (IBMFS), immunodeficiencies, anemias, and blood cancers. MYSM1 is a DNA binding protein and a regulator of gene expression, and we were among the first to demonstrate the critical role of MYSM1 in blood cell development in mouse models. Recently, mutations in MYSM1 were also identified in human IBMFS patients, highlighting the biomedical importance of understanding MYSM1 functions and mechanisms of action in hematopoiesis. In the current research program, we analyze (1) the role and mechanisms of MYSM1 activity in the regulation of gene expression in blood cell development, and (2) the cellular and molecular mechanisms driving the hematopoietic failure in MYSM1-deficiency. Building on our previous work, (1.1) we will identify the MYSM1-regulated genes in mouse HSPCs, (1.2-1.3) conduct the first comprehensive analysis of the mechanisms through which MYSM1 regulates gene expression, (2.1) analyze the molecular and causal links between MYSM1-loss, gene dysregulation, and HSPC dysfunction, and (2.2) conduct the first cellular and molecular analysis of the impact of MYSM1-deficiency on the development of the red blood cell lineage. These studies advance the fundamental understanding of the molecular networks regulating gene expression and blood cell development, and in the long-term may offer insights into IBMFS and other hematologic disorders, and suggest novel strategies for disease diagnosis, management, and treatment.
Program
Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
472655
Name
Nijnik Anastasia
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Hematology, Digestive Disease & Kidney
Projecttitle
Deubiquitinase MYSM1 as an essential epigenetic regulator of hematopoiesis
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)
Keyworddelim
Atac-Seq; Chip-Seq; Epigenetic Regulation; Erythropoiesis; Hematopoiesis; Hematopoietic Stem And Progenitor Cells; Inherited Bone Marrow Failure Syndrome; Ribosomopathy; Transcriptional Regulation; Transgenic/Knockout Mouse Models
Abstract
Our blood is sustained by the daily production of hundreds of billions of new cells in our bone marrow in the process known as hematopoiesis. This process requires precise regulation of gene expression within the hematopoietic stem and progenitor cells (HSPCs), and its dysregulation can result in devastating hematologic disorders, such as inherited bone marrow failures (IBMFS), immunodeficiencies, anemias, and blood cancers. MYSM1 is a DNA binding protein and a regulator of gene expression, and we were among the first to demonstrate the critical role of MYSM1 in blood cell development in mouse models. Recently, mutations in MYSM1 were also identified in human IBMFS patients, highlighting the biomedical importance of understanding MYSM1 functions and mechanisms of action in hematopoiesis. In the current research program, we analyze (1) the role and mechanisms of MYSM1 activity in the regulation of gene expression in blood cell development, and (2) the cellular and molecular mechanisms driving the hematopoietic failure in MYSM1-deficiency. Building on our previous work, (1.1) we will identify the MYSM1-regulated genes in mouse HSPCs, (1.2-1.3) conduct the first comprehensive analysis of the mechanisms through which MYSM1 regulates gene expression, (2.1) analyze the molecular and causal links between MYSM1-loss, gene dysregulation, and HSPC dysfunction, and (2.2) conduct the first cellular and molecular analysis of the impact of MYSM1-deficiency on the development of the red blood cell lineage. These studies advance the fundamental understanding of the molecular networks regulating gene expression and blood cell development, and in the long-term may offer insights into IBMFS and other hematologic disorders, and suggest novel strategies for disease diagnosis, management, and treatment.
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nijnik, Anastasia; Langlais, David
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~